What could you do if your data was working for you and not against you? With Bloomberg delivering

enterprise data directly to your systems, you get easy access to the details you want, optimized for

higher level analysis, and financial data experts committed to helping you maximize your every move.

Our data is made for more, so you can show the world what you're made of. Visit Bloomberg.com slash enterprise data to learn more.

Welcome to Prognosis. I'm Laura Carlson. It's day 321 since coronavirus was declared a global pandemic.

Today's main story, the CDC's new director has two tough jobs ahead, responding to the pandemic

and restoring the organization's battered reputation.

But first, here's what happened in virus news today.

Johnson & Johnson's one-shot vaccine generated strong protection against COVID-19 in a large late-stage trial.

The news raises hope that it can rapidly reshape a stumbling immunization campaign.

In a statement today, the company said that while the vaccine was shown to prevent 66% of moderate to severe

cases of COVID-19, it was particularly effective at keeping people from getting severely ill.

The shot also prevented 100% of hospitalizations and deaths.

J&J will deliver about 2 million doses of its COVID-19 vaccine

when it receives an emergency use authorization in the U.S.

That's according to a government accountability report, published yesterday.

J&J plans to file with the U.S. Food and Drug Administration for that authorization next week.

The European Union's drug regulator cleared a COVID-19 vaccine from AstraZeneca and the University

of Oxford for all adults today.

A shortfall in expected deliveries has raised tensions between

the company and the block. The Astra-Oxford vaccine will be the third available in the EU after

shots from Pfizer and Moderna. And it could help alleviate the shortage of shots in the region.

...